CD44 and glioblastoma: Common targets are GFAP (Wang et al., 2018), HSP70 (Sharifzad et al., 2020), VEGF (Nicolas et al., 2019), BDNF (Huo & Chen, 2019), ECM (Tejero et al., 2019), FN1 (Yu et al., 2020; Gu, Gu & Shou, 2014; Guo, Heller & Thorslund, 2016; Liao et al., 2018), CD44 (Mooney et al., 2016), Fransgelin-2, Short Hairpin RNAGLN and GRN (Ness, Riemenschneider & Baches., 2009; Trigos et al., 2019) etc. Previous research suggested that TAGLN2 might be involved in progression due to its higher expression in glioblastomas compared to IDH1/2 WT gliomas of lower grades (Beyer et al., 2018; Han et al., 2017).